To date, no GPX4 inhibitors have been approved for use in the clinic, and any such inhibitor may carry significant safety liabilities, as it has been shown that mice with a specific deletion of GPX4 in the kidney display acute renal failure (42). The gene discussed is GPX4; the disease is acute kidney injury.